08.10.2010
- Genzyme said that Sanofi-Aventis's chief executive had privately opened the door in September to paying as much as $80 per share for the U.S. company before going hostile with a...
07.10.2010
- Sanofi-Aventis finally made a hostile $18.5 billion tender offer for Genzyme, but it acknowledged that Genzyme's willingness, and possibly a higher price, may be needed to succeed...
04.10.2010
- French drugmaker Sanofi-Aventis launched a hostile bid for Genzyme at $69 per share, or $18.5 billion, setting off what could be a protracted battle for control of the U.S. biotech...
28.09.2010
- Sanofi-Aventis has not changed its offer of $69 per share for drugmaker Genzyme, a Sanofi spokesman said Monday, declining to comment on a report it may be lining up more funding...
20.09.2010
- An oil major, a luxury cosmetics company and independent directors including a former astronaut will have a key say in what may be the next multi-billion dollar merger to shake the...
17.09.2010
- Sanofi-Aventis sees a reasonable chance of buying U.S. biotech Genzyme at a fair price, but expects it will take some time to agree a deal that would further diversify the French...
17.09.2010
- Genzyme said it expects a broad cost-cutting program that includes laying off 1,000 employees over 15 months will boost profitability and allow it to invest in areas crucial to its...
14.09.2010
- U.S. biotech firm Genzyme said it agreed to sell its genetic-testing business to Labcorp of America Holdings for $925 million in cash. Genzyme, which recently rejected a takeover...
